References
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582–1589.
- Carrillo J, Izquierdo-Useros N, Avila-Nieto C, et al. Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. Biochem Biophys Res Commun. 2021;538:187–191.
- Nuccetelli M, Pieri M, Gisone F, et al. Evaluation of a new simultaneous anti-SARS-CoV-2 IgA, IgM and IgG screening automated assay based on native inactivated virus. Int Immunopharmacol. 2021;92:107330.
- Voysey M, Clemens SAC, Madhi SA, et al.; Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111.
- Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in russia. Lancet. 2021;397(10275):671–681.
- Sadoff J, Gray G, Vandebosch A, et al.; ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187–2201.
- Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021;27(2):205–211.
- WHO. WHO grants emergency approval for China’s Sinopharm COVID-19 vaccine. 2021. Available from: https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
- Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45.
- WHO. The Sinovac COVID-19 vaccine: What you need to know. 2021. Available from: https://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know?gclid=CjwKCAjwt8uGBhBAEiwAayu_9TQqrDdWEkSIsm9qOk6ks4Psg6-oncXb0KGOiAeu1RQY63DH-H3txBoCxmAQAvD_BwE
- COVAXIN. India's first indigenous COVID-19 vaccine | Bharat Biotech. 2021. Available from: https://www.bharatbiotech.com/covaxin.html
- Kariko K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008;16(11):1833–1840.
- Polack FP, Thomas SJ, Kitchin N, et al.; C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
- Rauch S, Gooch K, Hall Y, et al. mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection. bioRxiv. 2020.
- Rauch S, Roth N, Schwendt K, et al. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines. 2021;6(1):57.
- Kremsner P, Mann P, Bosch J, et al. Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers. medRxiv. 2020.
- Duffy S. Why are RNA virus mutation rates so damn high? PLoS Biol. 2018;16(8):e3000003
- Benedetti F, Pachetti M, Marini B, et al. SARS-CoV-2: March toward adaptation. J Med Virol. 2020;92(11):2274–2276.
- Domingo E. Viruses at the edge of adaptation. Virology. 2000;270(2):251–253.
- Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol. 1997;51:151–178.
- Pachetti M, Marini B, Benedetti F, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J Transl Med. 2020;18(1):179.
- van Dorp L, Acman M, Richard D, et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol. 2020;83:104351.
- Benvenuto D, Giovanetti M, Ciccozzi A, et al. The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med Virol. 2020;92(4):455–459.
- Benvenuto D, Demir AB, Giovanetti M, et al. Evidence for mutations in SARS-CoV-2 italian isolates potentially affecting virus transmission. J Med Virol. 2020;92(10):2232–2237.
- Thomson EC, Rosen LE, Shepherd JG, et al. COVID-19 Genomics UK (COG-UK) Consortium. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184(5):1171–1187 e20.
- van Oosterhout C, Hall N, Ly H, et al. COVID-19 evolution during the pandemic - Implications of new SARS-CoV-2 variants on disease control and public health policies. Virulence. 2021;12(1):507–508.
- Abdool Karim SS, de Oliveira T, Loots G. Appropriate names for COVID-19 variants. Science. 2021;371(6535):1215.
- Fiorentini S, Messali S, Zani A, et al. First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020. Lancet Infect Dis. 2021;21(6):e147.
- Srivastava S, Banu S, Singh P, et al. SARS-CoV-2 genomics: an Indian perspective on sequencing viral variants. J Biosci. 2021;46:22.
- PANGO lineages. P.1 report 2021. 2021. Available from: https://cov-lineages.org/global_report_P.1.html
- Faria NR, Claro IM, Candido D, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. 2021 [cited 2021 Feb 15]. Available from: https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586
- Kupferschmid K. Vaccine 2.0: Moderna and other companies plan tweaks that would protect against new coronavirus mutations. 2021. Available from: https://www.sciencemag.org/news/2021/01/vaccine-20-moderna-and-other-companies-plan-tweaks-would-protect-against-new
- Arora P, Kumar H, Panigrahi BK. Prediction and analysis of COVID-19 positive cases using deep learning models: a descriptive case study of India. Chaos Solitons Fractals. 2020;139:110017.
- Banu S, Jolly B, Mukherjee P, et al. A distinct phylogenetic cluster of indian severe acute respiratory syndrome coronavirus 2 Isolates. Open Forum Infect Dis. 2020;7(11):ofaa434.
- Madhi SA, Baillie V, Cutland CL, et al.; Wits-VIDA COVID Group. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885–1898.
- Rubin R. COVID-19 vaccines vs variants-determining how much immunity is enough. JAMA. 2021;325(13):1241–1243.
- Shinde V, Bhikha S, Hoosain Z, et al.; 2019nCoV-501 Study Group. Efficacy of NVX-CoV2373 COVID-19 vaccine against the B.1.351 variant. N Engl J Med. 2021;384(20):1899–1909.
- Mascola JR, Graham BS, Fauci AS. SARS-CoV-2 viral variants-tackling a moving target. JAMA. 2021;325(13):1261–1262.
- Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–1365.
- Public Health England. Vaccines highly effective against B.1.617.2 variant after 2 doses 2021. Available from: https://www.gov.uk/government/news/vaccines-highly-effective-against-b-1-617-2-variant-after-2-doses
- Bernal JL, Andrews N, Gower C, et al. Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv. 2021.
- Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384(22):2092–2101.
- Muir KL, Kallam A, Koepsell SA, et al. Thrombotic thrombocytopenia after Ad26.COV2.S vaccination. N Engl J Med. 2021;384(20):1964–1965.
- European Medicine Agency. COVID-19 Vaccine AstraZeneca: benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets. 2021. Available from: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots
- Medicines & Healthcare products Regulatory Agency. Coronavirus vaccine - weekly summary of Yellow Card reporting. 2021. Available from: https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting
- Ostergaard SD, Schmidt M, Horvath-Puho E, et al. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence? Lancet. 2021;397(10283):1441–1443.
- European Centre for Disease Prevention and Control. COVID-19 Vaccine Tracker. 2021. Available from: https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab
- Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following pfizer and moderna SARS-CoV-2 vaccination. Am J Hematol. 2021;96(5):534–537.
- Das BB, Kohli U, Ramachandran P, et al. Myopericarditis following mRNA COVID-19 vaccination in adolescents 12 through 18 years of age. J Pediatr. 2021. DOI: https://doi.org/10.1016/j.jpeds.2021.07.044
- Nuccetelli M, Pieri M, Grelli S, et al. SARS-CoV-2 infection serology: a useful tool to overcome lockdown? Cell Death Discov. 2020;6:38.
- Pieri M, Ciotti M, Carlozzi N, et al. SARS-CoV-2 infection serology validation of different methods: Usefulness of IgA in the early phase of infection. Clin Chim Acta. 2020;511:28–32.
- Padoan A, Cosma C, Sciacovelli L, et al. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med. 2020; 58(7):1081–1088.
- Muecksch F, Wise H, Batchelor B, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent Patients. J Infect Dis. 2021;223(3):389–398.
- Muruato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020;11(1):4059.
- Walker SN, Chokkalingam N, Reuschel EL, et al. SARS-CoV-2 assays to detect functional antibody responses that block ACE2 recognition in vaccinated animals and infected patients. J Clin Microbiol. 2020;58(11):e01533–20.
- Kristiansen PA, Page M, Bernasconi V, et al. WHO international standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347–1348.
- Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med. 2021;2(2):100204.